Eagle Pharmaceuticals Inc (EGRX) Return on Investment ROI from the second quarter of 2023 to second quarter of 2022 and for the year 2023, average high and low, overall ranking from Jun 30 2023 to Jun 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eagle Pharmaceuticals inc   (NASDAQ: EGRX)


Eagle Pharmaceuticals Inc's ROI from its second quarter of 2023 to the second quarter of 2022 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Eagle Pharmaceuticals Inc's ROI in the second quarter of 2023?
Eagle Pharmaceuticals inc achieved a return on average invested assets (ROI) of 4.02 % in its second quarter of 2023, which is below Eagle Pharmaceuticals Inc's average return on investment, which stands at 14.75%.

Despite the deterioration in its net income, company has improved ROI compared to the first quarter of 2023.

Within the Healthcare sector 157 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2023 quarter, so far to 1526, from total ROI ranking in the first quarter of 2023 at 2469.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter
Y / Y Investment Change TTM 36.13 % 38.11 % 26.33 % 7.64 % 2.18 %
Y / Y Net Income Change TTM -47.57 % - - - 530.95 %
Investment (TTM) in Millions 318 316 295 260 268
Return On Investment (TTM) 4.02 % -0.94 % 13.68 % 9.19 % 10.43 %
EGRX's Overall Ranking # 1526 # 2469 # 701 # 1087 # 1232
Seq. Investment Change TTM 4.38 % 9.39 % 12.49 % 5.98 % 5.9 %
Seq. Net Income Change TTM - - 67.48 % -6.62 % -36.43 %
Net Income (TTM) in Millions 12 -3 36 21 23

EGRX Company Profile >> Back to EGRX Roi Comparisons >> See Annual EGRX Return On Investment



Return On Investment EGRX's Ranking
Within: No.
Industry # 56
Sector # 158
Overall # 1526

Return On Investment Statistics
High Average Low
71.66 %
14.75 %
-19.37 %
(Mar 31 2017)   (March 31, 2016)







Financial Statements
Eagle Pharmaceuticals Inc's II. Quarter Investments $ 318 Millions EGRX's Balance sheet
Eagle Pharmaceuticals Inc's II. Quarter Income $ 5 Millions Quarterly EGRX's Income Statement
EGRX's Income by Division See EGRX's Income by Division


EGRX Annual Return On Investment (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Investments in Millions 295 179 215 216 199
Y / Y Investment Growth 64.52 % -16.62 % -0.29 % 8.45 % -10.7 %
Net Income in Millions 36 -9 12 14 32
Y / Y Net Income Growth - - -16.24 % -55.14 % -38.58 %
Annual Return On Investment 12.08 % -4.81 % 5.57 % 6.63 % 16.04 %


Annual Roi Comment
In the fiscal year 2022 ROI improved to 12.08 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
EGRX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for EGRX's Competitors
Subscribers only: Roi for Eagle Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for EGRX's Customers

Other Ratios
EGRX's Roa EGRX's Inventory Turnover Ratio EGRX's Growth Rates EGRX's Dividend Statistics
EGRX's Profitability Ratios EGRX's Asset Turnover Ratio EGRX's Dividend Growth
EGRX's Roe EGRX's Valuation Ratios EGRX's Financial Strength Ratios EGRX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2023, within Healthcare Sector ROI
Gilead Sciences Inc   10.96 %
Orasure Technologies Inc  10.94 %
Alpha Pro Tech Ltd   10.50 %
Globus Medical Inc   10.50 %
Schrodinger Inc   9.80 %
Johnson and Johnson  9.46 %
Option Care Health Inc   9.41 %
Neurocrine Biosciences Inc   9.40 %
Organon and Co   9.37 %
Cadre Holdings inc   9.24 %
Thorne Healthtech Inc   9.11 %
Dexcom Inc   8.96 %
Electromed Inc   8.88 %
Haemonetics Corporation  8.80 %
Stryker Corp  8.75 %
Lemaitre Vascular Inc   8.73 %
Abbott Laboratories  8.69 %
Encompass Health Corporation  8.18 %
Glucotrack Inc   8.16 %
Quest Diagnostics Inc  8.06 %
Align Technology inc   7.82 %
Healthcare Services Group Inc   7.74 %
Incyte Corporation  7.64 %
Henry Schein Inc   7.51 %
Maravai Lifesciences Holdings Inc   7.32 %
Charles River Laboratories International inc   7.21 %
Viemed Healthcare Inc   7.06 %
Lftd Partners Inc   6.97 %
Fonar Corporation  6.81 %
Alkermes Plc   6.79 %

Date modified: 2026-09-26T07:17:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.